Find a study
Browse recruiting studies near you — free to check, always your choice.
98 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Multiple sclerosis (MS)
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus
📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
- Anxiety
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
Testing a single oral dose medicine versus placebo for social anxiety in adults
📍 Vanda Investigational Site · Phoenix, AZ · +30 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.
- Multiple sclerosis (MS)
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Testing a modified ublituximab treatment for relapsing multiple sclerosis
📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
- Multiple sclerosis (MS)
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Testing safety of a twice-yearly medicine for early relapsing MS
📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.
- Obesity / overweight
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Testing a 52-week medicine versus placebo in adults with obstructive sleep apnea on CPAP
📍 Valley Clinical Trials · Northridge, CA · +12 more US sites · Get directions →
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
- Anxiety
Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy
Testing whether self-controlled nitrous oxide during vasectomy lowers pain and anxiety
📍 Beth Israel Deaconess Medical Center · Boston, MA · Get directions →
This study is being done to see if nitrous oxide during vasectomy decreases pain and anxiety, and also assess whether patients have better satisfaction when they control their own level of nitrous oxide during the procedure. If we find that patients experience less pain or anxiety with nitrous oxide, it could be suggested that self-adjusted nitrous oxide (SANO) may be a useful tool for improving experience of care during vasectomy.
- Obesity / overweight
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
Testing whether obesity genes predict weight loss from a diet and a medicine
📍 Columbia University Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to understand if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The main question\[s\] it aims to answer are: * In Aim One, the investigators propose to rigorously test the hypothesis that presence of the Taq1A A1+ polymorphism is associated with greater weight loss with NB compared with the A1- genotype.
- Obesity / overweight
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Testing how added dietary fiber and metformin, alone or together, affect insulin resistance and
📍 University of Alberta · Edmonton, Alberta · Get directions →
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM.
- Obesity / overweight
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Testing a weekly injection in people with obesity and sleep apnea to lose weight and improve sleep
📍 Dignity Health, Mercy Gilbert · Gilbert, AZ · +19 more US sites · Get directions →
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweight
Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
Testing medicines plus lifestyle counseling to manage weight regain after bariatric surgery
📍 University of California Irvine Medical Center · Orange, CA · Get directions →
This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.
- Obesity / overweight
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Testing a weekly under-the-skin injection to see effects on weight and diabetes markers
📍 Kailera Clinical Site · Cullman, AL · +34 more US sites · Get directions →
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
- Multiple sclerosis (MS)
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Testing whether combining a walking medication with physical therapy improves mobility in people
📍 MGH Institute of Health Professions · Boston, MA · Get directions →
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?
- Obesity / overweight
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Testing a weekly under-the-skin medicine to help adults with obesity lose weight
📍 South Broward Research LLC · Miramar, FL · +21 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweightType 2 diabetes
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Testing different doses of a medicine for weight loss in people with obesity or overweight and type
📍 Lakeview Clinical Research · Guntersville, AL · +33 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
- DepressionAnxiety
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Studying how gut bacteria in pregnant people relates to depression and anxiety
📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.
- DepressionAnxiety
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Testing a breathing mist of ketamine to reduce symptoms of major depression
📍 Maimonides Medical Center · Brooklyn, NY · Get directions →
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
- Obesity / overweight
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Testing whether setmelanotide improves weight loss, hunger, and life quality in children and adults
📍 University of Alabama · Birmingham, AL · +7 more US sites · Get directions →
This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO).
- Obesity / overweightType 2 diabetes
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
Testing a medicine to see its safety and weight-loss effects in adults with obesity or overweight
📍 CenExel Anaheim Clinical Trials · Anaheim, CA · +39 more US sites · Get directions →
The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight.
- Obesity / overweight
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Testing safety and effectiveness of weight-loss medicines for kids with obesity
📍 Carey Chronis MD Pediatric, Infant and Adolescent Medicine · Ventura, CA · +15 more US sites · Get directions →
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
- Multiple sclerosis (MS)
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Testing a drug called orelabrutinib versus placebo in people with PPMS
📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Obesity / overweight
Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.
Testing if an IV medicine during bariatric surgery reduces pain and inflammation in adults with
📍 Hospital de Especialidades Centro Medico Nacional Siglo XXI · Mexico City, Mexico City · Get directions →
The goal of this randomized clinical trial is to find out whether giving an intravenous lidocaine + dexmedetomidine combination (LIDEX) during laparoscopic bariatric surgery can lower post-operative pain, inflammation, and oxidative stress in adults with obesity. The main questions it aims to answer are: * Pain control: Does LIDEX reduce pain 24 hours after surgery, as measured with the International Pain Outcomes Questionnaire (IPOQ)?
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Testing eloralintide in people with sleep apnea and obesity
📍 Cullman Clinical Trials · Cullman, AL · +22 more US sites · Get directions →
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2.
- Obesity / overweightHigh blood pressure
Impact GLP-1 Agonists Following Bariatric
Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar
📍 University of Missouri Hospital · Columbia, MO · Get directions →
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.
- Obesity / overweight
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
Comparing HIV treatment medicines to see how they affect weight in people with obesity
📍 Hospital de infectología, Centro Médico Nacional La Raza · Mexico City, · Get directions →
Background:Historically, HIV infection was associated with significant weight loss. However, weight gain is now commonly observed after initiating antiretroviral therapy (ART), particularly in individuals underweight at baseline.
- DepressionAnxiety
Creatine for Depressed Male and Female Methamphetamine Users
Testing whether creatine helps depression and anxiety in people who use meth
📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
- Multiple sclerosis (MS)
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Comparing stem cell transplant vs best available treatment for relapsing multiple sclerosis
📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · +21 more US sites · Get directions →
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.
- Obesity / overweight
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Testing a weekly shot to see if it is practical and helps weight in some postmenopausal breast
📍 Weill Cornell Medicine · New York, NY · Get directions →
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health.
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Testing whether eloralintide helps people with obesity or overweight and type 2 diabetes lose weight
📍 Birmingham Clinical Research · Birmingham, AL · +39 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Testing a medicine called eloralintide in adults with obesity or overweight without type 2 diabetes
📍 MFA Clinical Research · Tuscaloosa, AL · +39 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
- Obesity / overweight
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Testing tradipitant for nausea and vomiting from GLP-1 medicines in adults with obesity or
📍 Vanda Investigational Site · Los Angeles, CA · +9 more US sites · Get directions →
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
- Multiple sclerosis (MS)
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Testing orelabrutinib versus placebo for people with non-active secondary progressive multiple
📍 Arizona Neuroscience Research, LLC · Phoenix, AZ · +12 more US sites · Get directions →
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS.
- Obesity / overweight
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Testing adding tirzepatide to ixekizumab for plaque psoriasis and weight issues
📍 Medical Dermatology Specialists · Phoenix, AZ · +39 more US sites · Get directions →
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Fibrosis Lessens After Metabolic Surgery
Testing whether metabolic surgery can reduce liver scarring in obesity
📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.
- Anxiety
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Testing whether genetic-guided dosing of a daily anxiety medicine helps kids
📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →
This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.
- Anxiety
Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study
Testing whether adding L-methylfolate is safe and tolerated for hard-to-treat anxiety
📍 Kingston Health Sciences Centre · Kingston, Ontario · Get directions →
The goal of this feasibility study is to determine the tolerability and safety of add on treatment with L-methylfolate in patients with treatment-resistant generalized anxiety disorder (GAD). The primary objective is to monitor for side effects and other risks associated with the treatment.
- Multiple sclerosis (MS)
Home Based Infusions for Ocrelizumab
Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis
📍 Amerita · Centennial, CO · Get directions →
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
- Multiple sclerosis (MS)
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Testing ozanimod versus fingolimod in children with multiple sclerosis
📍 Local Institution - 0114 · Loma Linda, CA · +11 more US sites · Get directions →
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
- Anxiety
Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generalized Anxiety Disorder
Testing a digital therapy device plus usual medicine vs usual medicine alone
📍 Servicios Especializados En Ensayos Clinicos, Seec, Sc · Mexico City, Mexico City · Get directions →
To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the change in the GAD-7 scale at 12 weeks of treatment, relative to baseline.
- Obesity / overweight
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Testing a weekly injection medicine for adults with obesity and knee arthritis pain
📍 Arizona Research Center, Inc. · Phoenix, AZ · +18 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweight
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Testing an injection treatment once a week for people with obesity to help maintain weight loss
📍 Pinnacle Research Group LLC · Anniston, AL · +12 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweightCrohn's / ulcerative colitis (IBD)
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Testing two medicines together to reduce ulcerative colitis symptoms and weight in adults with
📍 Digestive Health Specialists · Dothan, AL · +36 more US sites · Get directions →
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
- Obesity / overweightCrohn's / ulcerative colitis (IBD)
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Testing treatments for adults with Crohn’s disease and excess weight
📍 Digestive Health Specialists · Dothan, AL · +34 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
- Multiple sclerosis (MS)
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Testing how well and how safely remibrutinib works in secondary progressive multiple sclerosis
📍 Alabama Neurology Associates PC · Birmingham, AL · +32 more US sites · Get directions →
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
- Obesity / overweight
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Testing injections once a week to help adults with obesity and type 2 diabetes lose weight
📍 Univ of Alabama Birmingham · Birmingham, AL · +14 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweight
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Testing how well CagriSema and cagrilintide help children with obesity lose weight
📍 Neighborhood Healthcare · Escondido, CA · +33 more US sites · Get directions →
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study.
- DepressionAnxiety
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
Testing a cognitive training program to see brain and thinking changes in people with depression or
📍 UC San Diego · San Diego, CA · Get directions →
The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups.
- Multiple sclerosis (MS)💵 May compensate
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis
📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
- Obesity / overweight
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Testing a once-weekly under-the-skin injection for weight loss in adults with obesity or overweight
📍 Kailera Clinical Site · Anniston, AL · +22 more US sites · Get directions →
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Obesity / overweight
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Testing tirzepatide with healthy diet and exercise for teens with obesity
📍 Children's Hospital Los Angeles · Los Angeles, CA · +13 more US sites · Get directions →
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.
- Multiple sclerosis (MS)
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return
📍 Johns Hopkins University · Baltimore, MD · Get directions →
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
- Obesity / overweight
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Testing retatrutide to help people with obesity and chronic low back pain
📍 MD First Research - Chandler · Chandler, AZ · +24 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
- Obesity / overweightHeart / cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity
📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Obesity / overweightHeart / cardiovascular disease💵 May compensate
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people
📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).
- Obesity / overweightType 2 diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Testing different doses of CagriSema and semaglutide for weight loss in people with obesity, with or
📍 Uni of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants.
- Obesity / overweightHeart / cardiovascular disease
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Testing how well NNC0487-0111 works versus placebo in heart failure with excess body weight
📍 Advanced Cardiovascular, LLC · Alexander City, AL · +39 more US sites · Get directions →
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight.
- Obesity / overweight
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Testing a weekly under-the-skin medicine to help people with excess weight and sleep apnea lose
📍 Artemis Insitute for Clin Res · San Diego, CA · +16 more US sites · Get directions →
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweightHigh blood pressure💵 May compensate
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Testing treatments to lower high pressure in liver veins in people with advanced liver disease and
📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.
- Obesity / overweight
Food-Body-Mind Intervention (16 Weeks)
Testing a 16-week food, body, and mind program for preschoolers with obesity
📍 Community Action Agency · Jackson, MI · Get directions →
This novel, timely, and theory-driven Food-Body-Mind intervention addresses the national emergency of mental health crises in early childhood. By targeting Head Start racially/ethnically diverse preschoolers from low-income backgrounds in both urban and rural areas, this intervention is expected to contribute toward reducing health disparities and promoting health equity, a major priority of the NIH and Healthy People 2030.
- Obesity / overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Testing how safe and well people with obesity do after switching to a new diabetes-like weight drug
📍 Cahaba Research, Inc. · Pelham, AL · +39 more US sites · Get directions →
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Multiple sclerosis (MS)
Glucose Consumption in MS Using [F-18]FDG-PET
Testing how [F-18]FDG PET shows glucose use in people with MS and controls
📍 Brigham & Women's Hospital · Boston, MA · Get directions →
Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting MS (RRMS), as well as healthy controls.
- Showing the first 60 of 98. Add filters or a location to narrow down.